MEDICAL WEIGHT MANAGEMENT · SINGAPORE

Orforglipron: The Once-Daily GLP-1 Pill

Orforglipron is a small-molecule GLP-1 tablet for weight management that can be taken at any time of day, with or without food. Here is how it works, what the ATTAIN trials found, and where it stands in Singapore.

Struggling with weight loss for years?
Get a doctor-prescribed solution to regulate appetite and supports sustainable weight loss by addressing hormonal and metabolic factors.

-12.4%

Average weight change, top dose (1)

72 Weeks

ATTAIN-1 trial duration (1)

Any time

With or without food or water (3)

💡

A note on terminology

This page uses orforglipron, the generic name, rather than any brand name, in line with Singapore's medical advertising guidelines, which restrict reference to registered trade names.

Where orforglipron stands today

Orforglipron is new, so it helps to know exactly what has and hasn't been approved before you speak to a doctor.

✓ 2023 — Phase 2 results published. Early trials showed weight loss that increased with the dose over 36 weeks, which led to large phase 3 studies. (4)

✓ 2025 — Phase 3 ATTAIN trials reported. Two 72-week trials tested orforglipron in adults with obesity or overweight, one without diabetes and one with type 2 diabetes. (1) (2)

✓ April 2026 — Approved overseas for weight management. US regulators approved orforglipron for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. Approvals in the United Kingdom, the United Arab Emirates, Saudi Arabia and China followed later in 2026. (3)

▸ Singapore — Not yet registered. At the time of writing (November 2026), orforglipron is not registered with HSA, so doctors here cannot prescribe it. Please avoid overseas or online sellers: unregistered weight loss products may be fake or unsafe. (5) (6)

How does a GLP-1 pill work?

GLP-1 is a hormone the gut releases after you eat. It tells the brain you are full, slows how quickly the stomach empties, and helps the pancreas release insulin when blood sugar rises.

Most GLP-1 medicines are peptides, small proteins that stomach acid breaks down. That is why they are usually injected, and why the one existing GLP-1 tablet needs a strict empty-stomach routine to be absorbed.

Orforglipron is a small, non-peptide molecule that still switches on the GLP-1 receptor. It survives digestion, so it can be swallowed as an ordinary tablet once a day, at any time, with or without food. (3) (4)

Fig. 1 — Why orforglipron can be taken as a tablet: peptide versus small-molecule GLP-1.
Fig. 1 — Why orforglipron can be taken as a tablet: peptide versus small-molecule GLP-1.
Fig. 2 — From a daily tablet to gradual weight loss.
Fig. 2 — From a daily tablet to gradual weight loss.

What the ATTAIN trials found

ATTAIN-1 and ATTAIN-2 were phase 3, randomised, double-blind, placebo-controlled trials run over 72 weeks. Everyone taking part also received advice on diet and physical activity. (1) (2)

Trial

Population (n)

Weight change, top dose

Weight change, placebo

Type 2 diabetes

ATTAIN-1

3,127 · obesity or overweight

-12.4%

-0.9%

No

ATTAIN-2

1,613 · obesity or overweight

-10.5%

-2.2%

Yes

ATTAIN-1: adults without diabetes

At 72 weeks, people on the highest dose (36 mg) lost an average of 12.4% of their body weight, compared with 0.9% on placebo. Weight came off gradually and was still falling slowly towards the end of the trial. (1)

ATTAIN-2: adults with type 2 diabetes

People with type 2 diabetes usually lose less weight on GLP-1 medicines than people without it. On the highest dose, average weight loss was 10.5% versus 2.2% on placebo, alongside lower blood sugar (HbA1c). (2)

Fig. 3 — Average change in body weight at week 72 in ATTAIN-1 and ATTAIN-2, highest dose versus placebo.
Fig. 3 — Average change in body weight at week 72, highest dose versus placebo. Source: ATTAIN-1 and ATTAIN-2 (1)(2).
What else did the trials measure?

Besides body weight, the ATTAIN trials tracked several heart and metabolic markers. Orforglipron was associated with improvements in:

  • Waist circumference
  • Systolic blood pressure
  • Triglycerides
  • Non-HDL cholesterol
  • hs-CRP, a marker of inflammation
  • HbA1c, in people with type 2 diabetes

These were secondary measures. The trials were not designed to show whether orforglipron prevents heart attacks or strokes; longer studies looking at those outcomes are still running. (1) (2)

Because orforglipron has no fasting window, it can be taken alongside other morning medicines. A simpler routine can make it easier to stay on treatment, which matters, because weight loss medicines only work for as long as they are taken.

Why keeping weight off matters

When GLP-1 treatment stops, appetite usually returns and weight tends to come back. Researchers are now studying whether a daily tablet like orforglipron could help people hold on to their weight loss after a course of weekly injections. (7)

How does it compare with weekly injections?

Orforglipron joins a group of GLP-1 medicines that already includes weekly semaglutide and tirzepatide injections. Here is how they compare on the evidence so far.

In their own phase 3 trials, weekly semaglutide 2.4 mg produced average weight loss of about 15% over 68 weeks, and weekly tirzepatide about 21% at its highest dose over 72 weeks. (8) (9)

Orforglipron's average result, about 11 to 12%, is lower. The trials enrolled different people and were not run head to head, though, so the numbers can't be compared directly.

The trade-off is convenience: one tablet a day, no needles and no timing rules. For some people, that makes long-term treatment easier to keep up. A doctor can help you weigh these factors against your health goals.

Fig. 4 — Orforglipron versus weekly GLP-1 injections at a glance.
Fig. 4 — Orforglipron versus weekly GLP-1 injections at a glance.

Side effects and tolerability

Side effects in the ATTAIN trials were similar to other GLP-1 medicines. Most were gastrointestinal, mild to moderate, and happened mainly while the dose was being increased. More people stopped orforglipron because of side effects than stopped placebo. (1) (2)

Commonly reported effects

  • Nausea
  • Constipation
  • Diarrhoea
  • Vomiting
  • Indigestion
  • Reduced appetite
Book a Consultation & Check Your Eligibility
Weight loss can sometimes feel overwhelming and challenging. However, you do not have to face it alone. With the right treatment plan and professional guidance, you can achieve sustainable weight loss and reclaim your health with confidence.

Schedule a consultation with us today for a comprehensive body analysis and personalised treatment plan.
BOOK A CONSULTATION
Frequently asked questions
References

Studies and sources cited in this document

  1. Wharton S, et al., for the ATTAIN-1 Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, for Obesity. N Engl J Med. 2025.
  2. Eli Lilly and Company. ATTAIN-2: orforglipron in adults with obesity or overweight and type 2 diabetes. Topline phase 3 results, 2025.
  3. U.S. Food and Drug Administration. Approval of orforglipron for chronic weight management in adults. April 1, 2026.
  4. Wharton S, Blevins T, Connery L, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023;389:877-888.
  5. Health Sciences Authority, Singapore. Register of Therapeutic Products. Checked November 2026.
  6. Health Sciences Authority, Singapore. Public advisories on illegal and unregistered weight loss products.
  7. Eli Lilly and Company. ATTAIN-MAINTAIN: a phase 3 study of orforglipron to maintain weight loss after injectable GLP-1 treatment.
  8. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
  9. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.

Detect any underlying health conditions.

When was the last time you had your full medical check up? Take charge of your own health – Begin with a comprehensive full body medical check-up and speak to your doctor.

Please indicate your current problem or share any other remarks for us to note before your appointment.

Take charge of your health today.

Your submission has been received.
Your submission has been received. Our customer representative will contact you soon! For quicker response, please call us at +65 8129 8877
Oops! Something went wrong while submitting the form.